**Background and objectives:** WHO has been organising CROI-affiliated TB/HIV meetings in collaboration with partners since 2007. These data-driven meetings serve as a platform of networking to discuss novel research ideas, controversies and played a crucial role in catalysing policies and programmes. For the reports of research meetings from previous years please see the following link. The main aim of the proposed meeting in 2018 is to stimulate high level scientific debate around the opportunities, challenges, and scientific research implications posed by the latest short-course rifamycin-based TB preventive regimens in the context of scale-up of the latest generation of HIV integrase inhibitors such as dolutegravir. The meeting will discuss, debate and highlight WHO’s Updated and Consolidated Guidelines on the Programmatic Management of Latent Tuberculosis Infection; research landscapes and options for TB preventive treatment and the new generation of antiretrovirals; and implications for countries and for the design of clinical trials for TB prevention and new antiretroviral drugs. A light lunch will be served during the meeting.

**Participants:** HIV and TB researchers, implementers and public health policy makers.

Attendance at the meeting will be by invitation only and on a first come, first serve basis. If you are interested in participating please notify us of your interest at tbhiv@who.int at your earliest convenience but no later than close of business on 23 February 2018.

---

**Provisional Agenda**

**Chairs:** Constance Benson, University of California, San Diego, USA and Richard Chaisson, Johns Hopkins Medicine, USA

**Conveners:** Meg Doherty and Haileyesus Getahun, WHO, Switzerland

**11:30-11:35:** Introduction and objectives of the meeting

**11:35-11:55:** Updated and Consolidated Guidelines on the Programmatic Management of Latent Tuberculosis Infection: pushing the horizons *(Haileyesus Getahun)*

**11:55-12:15:** Discussion

**12:15-12:35:** Short-course Rifamycin-based regimens: Why countries should scale up this silver bullet for TB prevention among PLHIV *(Kelly E Dooley, Johns Hopkins Medicine, USA)*

**12:35-12:55:** Dolutegravir: why countries should scale up this silver bullet for HIV treatment. *(Francois Venter, Wits Reproductive Health and HIV Institute (Wits RHI), South Africa)*

**12:55-13:05:** Implications for research priorities *(Discussant to be advised)*

**13:05-13:25:** Discussion

**13:25-13:30:** General conclusion and next steps